NASDAQ:PRPO Precipio Q3 2026 Earnings Date & Estimates $20.36 -0.25 (-1.23%) As of 03:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Precipio is estimated to report Q3 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for November 13, 2026 at 2:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 16, 2026Conference Call DateNovember 13, 2026Conference Call2:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Precipio in Q3 2026Precipio is expected to post earnings of -$2.00 per share on revenue of $1.68 million. In the same quarter a year earlier Precipio reported -$0.05 per share on revenue of $6.77 million. Precipio last reported on August 14, 2026, posting -$0.12 per share and beating the -$2.00 consensus estimate.Consensus EstimatesConsensus EPS-$2.00Expected Revenue$1.68 millionPrior-Year EPS-$0.05Prior-Year Revenue$6.77 millionExpected Revenue Growth-75.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.12 (Beat by +$1.88)Last Quarter Revenue$7.02 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Precipio Q3 2026 Earnings FAQ When does Precipio report Q3 2026 earnings? Precipio (NASDAQ:PRPO) is estimated to report Q3 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Precipio's Q3 2026 earnings call? Precipio's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 2:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Precipio? Analysts expect Precipio to post earnings of -$2.00 per share for Q3 2026. How much revenue is Precipio expected to report? The consensus revenue estimate for Precipio is $1.68 million for Q3 2026. Precipio Earnings HeadlinesPrecipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average - Here's WhyOctober 23 at 3:41 AM | americanbankingnews.comPrecipio (NASDAQ:PRPO) Shares Break Below Two Hundred Day Moving Average - What's Next?October 15, 2026 | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 23 at 1:00 AM | Base Camp Trading (Ad)Precipio: Management Dreams Big, Institutions Have A Toe InOctober 12, 2026 | seekingalpha.comPrecipio, Inc. (PRPO) Q2 2026 Earnings Call TranscriptAugust 17, 2026 | seekingalpha.comPrecipio Announces Q2-2026 Financial ResultsAugust 14, 2026 | globenewswire.comSee More Precipio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email. Email Address About PrecipioPrecipio (NASDAQ:PRPO) is a biotechnology and diagnostic company focused on improving the detection and classification of cancer, particularly hematologic malignancies such as leukemia and lymphoma. The company combines laboratory testing, diagnostic products and specialized pathology expertise to support more accurate cancer diagnoses. Precipio operates a clinical laboratory that provides hematopathology and molecular diagnostic services to physicians, hospitals and other healthcare organizations. Its offerings include testing designed to identify genetic and cellular abnormalities associated with blood cancers, helping clinicians make treatment and monitoring decisions. The company also develops and commercializes diagnostic technologies, including its HemeScreen platform for molecular testing in hematologic cancers and laboratory products intended to improve the performance and consistency of cytogenetic testing. Precipio is based in New Haven, Connecticut, and its services and products are marketed to healthcare providers and laboratories in the United States and select international markets.View Precipio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsPalantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's Why Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
